Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

Zhong Chen; Dayong Wu; Jennifer M. Thomas-Ahner; Changxue Lu; Pei Zhao; Qingfu Zhang; Connor Geraghty; Pearlly S. Yan; William Hankey; Benjamin Sunkel; Xiaolong Cheng; Emmanuel S. Antonarakis; Qi En Wang; Zhihua Liu; Tim H.M. Huang; Victor X. Jin; Steven K. Clinton; Jun Luo; Jiaoti Huang; Qianben Wang

doi:10.1073/pnas.1718811115

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

Zhong Chen, Dayong Wu, Jennifer M. Thomas-Ahner, Changxue Lu, Pei Zhao, Qingfu Zhang, Connor Geraghty, Pearlly S. Yan, William Hankey, Benjamin Sunkel, Xiaolong Cheng, Emmanuel S. Antonarakis, Qi En Wang, Zhihua Liu, Tim H.M. Huang, Victor X. Jin, Steven K. Clinton, Jun Luo, Jiaoti Huang, Qianben Wang

Department of Molecular Medicine

Resultado de la investigación: Article › revisión exhaustiva

81 Citas (Scopus)

Resumen

The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7–driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7–driven prostate tumors.

Idioma original	English (US)
Páginas (desde-hasta)	6810-6815
Número de páginas	6
Publicación	Proceedings of the National Academy of Sciences of the United States of America
Volumen	115
N.º	26
DOI	https://doi.org/10.1073/pnas.1718811115
Estado	Published - jun. 26 2018

ASJC Scopus subject areas

General

Acceder al documento

10.1073/pnas.1718811115

Otros archivos y enlaces

Citar esto

Chen, Z., Wu, D., Thomas-Ahner, J. M., Lu, C., Zhao, P., Zhang, Q., Geraghty, C., Yan, P. S., Hankey, W., Sunkel, B., Cheng, X., Antonarakis, E. S., Wang, Q. E., Liu, Z., Huang, T. H. M., Jin, V. X., Clinton, S. K., Luo, J., Huang, J., & Wang, Q. (2018). Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proceedings of the National Academy of Sciences of the United States of America, 115(26), 6810-6815. https://doi.org/10.1073/pnas.1718811115

Chen, Z, Wu, D, Thomas-Ahner, JM, Lu, C, Zhao, P, Zhang, Q, Geraghty, C, Yan, PS, Hankey, W, Sunkel, B, Cheng, X, Antonarakis, ES, Wang, QE, Liu, Z, Huang, THM, Jin, VX, Clinton, SK, Luo, J, Huang, J & Wang, Q 2018, 'Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13', Proceedings of the National Academy of Sciences of the United States of America, vol. 115, n.º 26, pp. 6810-6815. https://doi.org/10.1073/pnas.1718811115

@article{fb313998415c4ddf825ba1c8d9bff9da,

title = "Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13",

abstract = "The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7–driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7–driven prostate tumors.",

keywords = "AR-V7, Castration-resistant prostate cancer, HoxB13, Motif-resolution cistromes",

author = "Zhong Chen and Dayong Wu and Thomas-Ahner, {Jennifer M.} and Changxue Lu and Pei Zhao and Qingfu Zhang and Connor Geraghty and Yan, {Pearlly S.} and William Hankey and Benjamin Sunkel and Xiaolong Cheng and Antonarakis, {Emmanuel S.} and Wang, {Qi En} and Zhihua Liu and Huang, {Tim H.M.} and Jin, {Victor X.} and Clinton, {Steven K.} and Jun Luo and Jiaoti Huang and Qianben Wang",

note = "Funding Information: ACKNOWLEDGMENTS. This work was supported by NIH Grants U54 CA217297 (to Q.W., V.X.J., and T.H.-M.H.), R01 GM120221 (to Q.W.), R01 CA200853 (to Q.W., J.H., and S.K.C.), R01 CA172603, R01 CA205001, and R01 CA212403 (to J.H.); Department of Defense Grant W81XWH-16-1-0291 (to Q.W., S.K.C., and J.H.); and the Prostate Cancer Foundation Joyce and Larry Stupski Prostate Cancer Precision Oncology Special Challenge Award (to J.H.). Publisher Copyright: {\textcopyright} 2018 National Academy of Sciences. All Rights Reserved.",

year = "2018",

month = jun,

day = "26",

doi = "10.1073/pnas.1718811115",

language = "English (US)",

volume = "115",

pages = "6810--6815",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "26",

}

TY - JOUR

T1 - Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

AU - Chen, Zhong

AU - Wu, Dayong

AU - Thomas-Ahner, Jennifer M.

AU - Lu, Changxue

AU - Zhao, Pei

AU - Zhang, Qingfu

AU - Geraghty, Connor

AU - Yan, Pearlly S.

AU - Hankey, William

AU - Sunkel, Benjamin

AU - Cheng, Xiaolong

AU - Antonarakis, Emmanuel S.

AU - Wang, Qi En

AU - Liu, Zhihua

AU - Huang, Tim H.M.

AU - Jin, Victor X.

AU - Clinton, Steven K.

AU - Luo, Jun

AU - Huang, Jiaoti

AU - Wang, Qianben

N1 - Funding Information: ACKNOWLEDGMENTS. This work was supported by NIH Grants U54 CA217297 (to Q.W., V.X.J., and T.H.-M.H.), R01 GM120221 (to Q.W.), R01 CA200853 (to Q.W., J.H., and S.K.C.), R01 CA172603, R01 CA205001, and R01 CA212403 (to J.H.); Department of Defense Grant W81XWH-16-1-0291 (to Q.W., S.K.C., and J.H.); and the Prostate Cancer Foundation Joyce and Larry Stupski Prostate Cancer Precision Oncology Special Challenge Award (to J.H.). Publisher Copyright: © 2018 National Academy of Sciences. All Rights Reserved.

PY - 2018/6/26

Y1 - 2018/6/26

N2 - The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7–driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7–driven prostate tumors.

AB - The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker studies established the role of AR-V7 in resistance to AR-targeting therapies, how AR-V7 mediates genomic functions in CRPC remains largely unknown. Using a ChIP-exo approach, we show AR-V7 binds to distinct genomic regions and recognizes a full-length androgen-responsive element in CRPC cells and patient tissues. Remarkably, we find dramatic differences in AR-V7 cistromes across diverse CRPC cells and patient tissues, regulating different target gene sets involved in CRPC progression. Surprisingly, we discover that HoxB13 is universally required for and colocalizes with AR-V7 binding to open chromatin across CRPC genomes. HoxB13 pioneers AR-V7 binding through direct physical interaction, and collaborates with AR-V7 to up-regulate target oncogenes. Transcriptional coregulation by HoxB13 and AR-V7 was further supported by their coexpression in tumors and circulating tumor cells from CRPC patients. Importantly, HoxB13 silencing significantly decreases CRPC growth through inhibition of AR-V7 oncogenic function. These results identify HoxB13 as a pivotal upstream regulator of AR-V7–driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7–driven prostate tumors.

KW - AR-V7

KW - Castration-resistant prostate cancer

KW - HoxB13

KW - Motif-resolution cistromes

UR - http://www.scopus.com/inward/record.url?scp=85049003766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049003766&partnerID=8YFLogxK

U2 - 10.1073/pnas.1718811115

DO - 10.1073/pnas.1718811115

M3 - Article

C2 - 29844167

AN - SCOPUS:85049003766

VL - 115

SP - 6810

EP - 6815

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto